Real world studies now support the findings of randomised control trials which prove the efficacy of Nucala (mepolizumab) in adults with severe eosinophilic asthma.1,2
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg subcutaneously (SC) once every 4 weeks in adults and adolescents 12 years and older. The licenced dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight.1
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
June 2022 | PM-GB-MPL-WCNT-200040 (V4.0)